Down-regulation of deoxycytidine kinase in human leukemic cell lines resistant to cladribine and clofarabine and increased ribonucleotide reductase activity contributes to fludarabine resistance.

No abstract is available for this paper.

• Publication year

  2003

• Venue

  Biochemical Pharmacology

• Publication date

  2003-01-15

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/S0006-2952(02)01484-3PMID 12504799
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Chromosomal Imbalances in Diffuse Large B-Cell Lymphoma Detected by Comparative Genomic Hybridization

  2002cited by this paper
• Real-time quantitative PCR assays for deoxycytidine kinase, deoxyguanosine kinase and 5’-nucleotidase mRNA measurement in cell lines and in patients with leukemia

  2002cited by this paper
• Resistance of leukemic cells to 2-chlorodeoxyadenosine is due to a lack of calcium-dependent cytochrome c release.

  2002cited by this paper
• Expression of high Km 5'-nucleotidase in leukemic blasts is an independent prognostic factor in adults with acute myeloid leukemia.

  2001cited by this paper
• Mammalian p53R2 Protein Forms an Active Ribonucleotide Reductasein Vitro with the R1 Protein, Which Is Expressed Both in Resting Cells in Response to DNA Damage and in Proliferating Cells*

  2001cited by this paper
• Human Cytosolic 5′-Nucleotidase I

  2001cited by this paper
• Multidrug-resistance protein 5 is a multispecific organic anion transporter able to transport nucleotide analogs.

  2000cited by this paper
• Deoxyadenosine analogs induce programmed cell death in chronic lymphocytic leukemia cells by damaging the DNA and by directly affecting the mitochondria.

  2000cited by this paper
• Cellular adaptation to down-regulated iron transport into lymphoid leukaemic cells: effects on the expression of the gene for ribonucleotide reductase.

  2000cited by this paper
• Expression of an Altered Ribonucleotide Reductase Activity Associated with the Replication of Murine Cytomegalovirus in Quiescent Fibroblasts

  2000cited by this paper
• Mitochondrial and submitochondrial localization of human deoxyguanosine kinase.

  2000cited by this paper
• A ribonucleotide reductase gene involved in a p53-dependent cell-cycle checkpoint for DNA damage

  2000cited by this paper
• Overexpression of ribonucleotide reductase as a mechanism of resistance to 2,2-difluorodeoxycytidine in the human KB cancer cell line.

  1999cited by this paper
• Common resistance mechanisms to deoxynucleoside analogues in variants of the human erythroleukaemic line K562

  1999cited by this paper
• Molecular and biochemical mechanisms of fludarabine and cladribine resistance in a human promyelocytic cell line.

  1999cited by this paper
• Differentiation of the mononuclear phagocyte system during mouse embryogenesis: the role of transcription factor PU.1.

  1999cited by this paper
• Biochemical pharmacology and resistance to 2-chloro-2'-arabino-fluoro-2'-deoxyadenosine, a novel analogue of cladribine in human leukemic cells.

  1999cited by this paper
• The Intracellular Localization of Deoxycytidine Kinase*

  1998cited by this paper
• Induction of an apoptotic program in cell-free extracts by 2-chloro-2'-deoxyadenosine 5'-triphosphate and cytochrome c.

  1998cited by this paper
• Analysis of DNA methylation of the 5' region of the deoxycytidine kinase gene in CCRF-CEM-sensitive and cladribine (CdA)- and 2-chloro-2'-arabino-fluoro-2'-deoxyadenosine (CAFdA)-resistant cells.

  1998cited by this paper
• Pharmacokinetics of cladribine in plasma and its 5'-monophosphate and 5'-triphosphate in leukemic cells of patients with chronic lymphocytic leukemia.

  1998cited by this paper
• Ribonucleotide reductases.

  1998cited by this paper
• Mechanisms responsible for resistance of sublines derived from leukemia cell lines to an antitumor agent 9-β-d-arabinofuranosyl-2-fluoroadenine

  1998cited by this paper
• 2‐Chlorodeoxyadenosine in the treatment of relapsed/refractory chronic lymphoproliferative disorders

  1997cited by this paper
• Deoxynucleotide pool depletion and sustained inhibition of ribonucleotide reductase and DNA synthesis after treatment of human lymphoblastoid cells with 2-chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl) adenine.

  1996cited by this paper
• Determination of 2-chloro-2'-deoxyadenosine nucleotides in leukemic cells by ion-pair high-performance liquid chromatography.

  1996cited by this paper
• Expression of deoxycytidine kinase and phosphorylation of 2-chlorodeoxyadenosine in human normal and tumour cells and tissues.

  1995cited by this paper
• Multidrug resistance gene (mdr1) RNA levels in relation to P-glycoprotein content of leukemic cells from patients with acute leukemia

  1995cited by this paper
• Mammalian deoxyribonucleoside kinases.

  1995cited by this paper
• Regulation of low Km (ecto-) 5'-nucleotidase gene expression in leukemic cells.

  1994cited by this paper
• Characterization of a hydroxyurea-resistant human KB cell line with supersensitivity to 6-thioguanine.

  1994cited by this paper
• Comparative genomic hybridization for molecular cytogenetic analysis of solid tumors.

  1992cited by this paper
• Response to 2-chlorodeoxyadenosine in patients with B-cell chronic lymphocytic leukemia resistant to fludarabine.

  1992cited by this paper
• Oral antilymphocyte activity and induction of apoptosis by 2-chloro-2'-arabino-fluoro-2'-deoxyadenosine.

  1992cited by this paper
• 2-Chlorodeoxyadenosine treatment of low-grade lymphomas.

  1992cited by this paper
• Resistance to 1-beta-D-arabinofuranosylcytosine in human T-lymphoblasts mediated by mutations within the deoxycytidine kinase gene.

  1992cited by this paper
• Comparison of the substrate specificities of human thymidine kinase 1 and 2 and deoxycytidine kinase toward antiviral and cytostatic nucleoside analogs.

  1991cited by this paper
• Effects of 2-chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)adenine on K562 cellular metabolism and the inhibition of human ribonucleotide reductase and DNA polymerases by its 5'-triphosphate.

  1991cited by this paper
• Effects of thymidine and hydroxyurea on the metabolism and cytotoxicity of 1-B-D arabinofuranosylcytosine in highly resistant human leukemia cells.

  1991cited by this paper
• A phase I clinical trial of 2-chlorodeoxyadenosine in pediatric patients with acute leukemia.

  1991cited by this paper
• Metabolism and action of purine nucleoside analogs.

  1991cited by this paper
• Induction of deoxycytidine kinase by 5-azacytidine in an HL-60 cell line resistant to arabinosylcytosine.

  1991cited by this paper
• 2-Chlorodeoxyadenosine: an effective new agent for the treatment of chronic lymphocytic leukemia.

  1988cited by this paper
• Sequential hydroxyurea-cytarabine chemotherapy for refractory non-Hodgkin's lymphoma.

  1987cited by this paper
• Inhibition of nucleoside diphosphate reductase by hydroxybenzohydroxamic acid derivatives.

  1985cited by this paper
• Modulation of cytarabine metabolism in the human promyelocytic leukemia cell line HL-60 by polyhydroxy-substituted benzohydroxamic acids.

  1982cited by this paper
• Simultaneous determination of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate and 3-deazauridine 5'-triphosphate in human leukemia cells by high-performance liquid chromatography.

  1980cited by this paper
• Alterations leading to increased ribonucleotide reductase in cells selected for resistance to deoxynucleosides.

  1974cited by this paper
• A rapid assay for CDP reductase activity in mammalian cell extracts.

  1970cited by this paper

• Ribonucleotide reductase (RNR) inhibitors as target-based weapon for future cancer drug development.

  2025cites this paper
• Discovery of a novel non-toxic analog of clofarabine for the treatment of triple negative breast cancer.

  2025cites this paper
• Coaxially fabricated electrospinning near-infrared light-responsive nanofibrous membranes for combating drug-resistant bacteria.

  2025cites this paper
• The PPP2R1A cancer hotspot mutant p.R183W increases clofarabine resistance in uterine serous carcinoma cells by a gain-of-function mechanism

  2024cites this paper
• Combination of Tissue Microarray Profiling and Multiplexed IHC Approaches to Investigate Transport Mechanism of Nucleoside Analog Drug Resistance.

  2023cites this paper
• ENT1 blockade by CNX-774 overcomes resistance to DHODH inhibition in pancreatic cancer.

  2022cites this paper
• Is Monitoring of the Intracellular Active Metabolite Levels of Nucleobase and Nucleoside Analogs Ready for Precision Medicine Applications?

  2022cites this paper
• Deciphering molecular mechanisms underlying chemoresistance in relapsed AML patients: towards precision medicine overcoming drug resistance

  2021cites this paper
• Cost-Effectiveness Analysis of Tisagenlecleucel, Blinatumomab, and Clofarabine for Treatment of B-cell Precursor Acute Lymphoblastic Leukemia

  2021cites this paper
• Clofarabine induces ERK/MSK/CREB activation through inhibiting CD99 on Ewing sarcoma cells

  2021cites this paper
• Surmounting Cytarabine-resistance in acute myeloblastic leukemia cells and specimens with a synergistic combination of hydroxyurea and azidothymidine

  2019cites this paper
• MicroRNAs Mediated Regulation of Expression of Nucleoside Analog Pathway Genes in Acute Myeloid Leukemia

  2019cites this paper
• Cladribine: mechanisms and mysteries in multiple sclerosis

  2018cites this paper
• Management of Refractory/Relapsed Acute Leukemia with Heart Limitation by Anthracycline-free Chemotherapy Regimens in Pediatric Patients: New Hypothesis and New Approach

  2018cites this paper
• Clofarabine: Structure, Mechanism of Action, and Clinical Pharmacology

  2017cites this paper
• Proteomic analysis of soluble and transmembrane proteins in human lymphoma cells

  2017cites this paper
• Melatonin overcomes resistance to clofarabine in two leukemic cell lines by increased expression of deoxycytidine kinase.

  2015cites this paper
• Nucleoside Analog Activity in Malignant Melanoma Cell Lines

  2015cites this paper
• Design and synthesis of potential ribonucleotide reductase enzyme (RNR) inhibitors as antileukemic and/or antiviral 2′-deoxymethylene nucleosides

  2015cites this paper
• Detailed Functional and Proteomic Characterization of Fludarabine Resistance in Mantle Cell Lymphoma Cells

  2015cites this paper
• Phospholipid derivatives of cladribine and fludarabine: synthesis and biological properties.

  2015cites this paper
• AAML0523: A report from the Children's Oncology Group on the efficacy of clofarabine in combination with cytarabine in pediatric patients with recurrent acute myeloid leukemia

  2014cites this paper
• Studies of overcoming acquired resistance : molecular mechanisms and development of novel drugs

  2014cites this paper
• Ribonucleotide reductase and cancer: biological mechanisms and targeted therapies

  2014cites this paper
• Phase I/II trial of clofarabine and cytarabine in children with relapsed/refractory acute lymphoblastic leukemia (AAML0523): A report from the Children's Oncology Group

  2013cites this paper
• Novel leukemic cell lines resistant to clofarabine by mechanisms of decreased active metabolite and increased antiapoptosis

  2013cites this paper
• Therapeutic perspectives for cN-II in cancer.

  2013cites this paper
• Homogeneous assay for real-time and simultaneous detection of thymidine kinase 1 and deoxycytidine kinase activities.

  2013cites this paper
• Bystander killing of malignant cells via the delivery of engineered thymidine-active deoxycytidine kinase for suicide gene therapy of cancer

  2012cites this paper
• Synergism between clofarabine and decitabine through p53R2: a pharmacodynamic drug-drug interaction modeling.

  2012cites this paper
• Radiolabeled nucleosides for predicting and monitoring the cancer therapeutic efficacy of chemodrugs.

  2012cites this paper
• Development of Novel Cell Fate Control Gene Therapy for Applications in Cancer and Immune Disorders

  2012cites this paper
• Preclinical rationale for synergistic interaction of pemetrexed and cytotoxic nucleoside analogues.

  2012cites this paper
• Expression status of ribonucleotide reductase small subunits hRRM2/p53R2 as prognostic biomarkers in stage I and II non-small cell lung cancer.

  2011cites this paper
• The synergistic cytotoxicity of clofarabine, fludarabine and busulfan in AML cells involves ATM pathway activation and chromatin remodeling.

  2011cites this paper
• Beyond hairy cell: the activity of cladribine in other hematologic malignancies.

  2010cites this paper
• Metabolic limitations of the use of nucleoside analogs in cancer therapy may be overcome by application of nanoparticles as drug carriers: A review

  2010cites this paper
• Investigation of the effects of adenosine and purine nucleoside analogues on the viability of human breast cancer cells

  2010cites this paper
• Novel Potent Inhibitors of Deoxycytidine Kinase Identified and Compared by Multiple Assays

  2010cites this paper
• [Prolonged bone marrow aplasia in patients with acute leukemia after chemotherapy].

  2010cites this paper
• Differences in cytosolic and mitochondrial 5'-nucleotidase and deoxynucleoside kinase activities in Sprague-Dawley rat and CD-1 mouse tissues: implication for the toxicity of nucleoside analogs in animal models.

  2010cites this paper
• The role of 5'-nucleotidases and Deoxynucleoside Kinases in Responses to Nucleoside Analogues

  2010influential citation
• Optimization and evaluation of electroporation delivery of siRNA in the human leukemic CEM cell line

  2010cites this paper
• Nucleoside analog cytotoxicity ‐focus on enzyme regulation, metabolism, and development of resistance

  2010influential citation
• Use of clofarabine for acute childhood leukemia

  2010cites this paper
• Mechanisms of anti-cancer action and pharmacology of clofarabine.

  2009cites this paper
• Phase II study of clofarabine in pediatric patients with refractory or relapsed acute myeloid leukemia.

  2009cites this paper
• Regulation of p53R2 and its role as potential target for cancer therapy.

  2009cites this paper
• A multi-center phase I study of clofarabine, etoposide and cyclophosphamide in combination in pediatric patients with refractory or relapsed acute leukemia

  2009cites this paper
• Synthesis and Antitumor Activity of a Heterodinucleotide of BVDU and Gemcitabine

  2008cites this paper
• Two distinct molecular mechanisms underlying cytarabine resistance in human leukemic cells.

  2008cites this paper
• RNAi Depletion of Deoxycytidine and Deoxyguanosine Kinase in Human Leukemic CEM Cells

  2008cites this paper
• Cytotoxic activity of gemcitabine and correlation with expression profile of drug-related genes in human lymphoid cells.

  2007cites this paper
• Ribonucleotide reductase: a critical enzyme for cancer chemotherapy and antiviral agents.

  2007cites this paper
• Fludarabine-mediated circumvention of cytarabine resistance is associated with fludarabine triphosphate accumulation in cytarabine-resistant leukemic cells

  2007cites this paper
• Nucleoside analogue delivery systems in cancer therapy

  2007influential citation
• Review of recent studies on resistance to cytotoxic deoxynucleoside analogues.

  2007cites this paper
• An increase of cytochrome C oxidase mediated disruption of gemcitabine incorporation into DNA in a resistant KB clone.

  2007cites this paper
• Cell cycle effect on the activity of deoxynucleoside analogue metabolising enzymes.

  2007cites this paper
• The Role of Deoxycytidine Kinase in DNA Synthesis and Nucleoside Analog Activation

  2006cites this paper
• The determinants of sensitivity and acquired resistance to gemcitabine differ in non–small cell lung cancer: a role of ABCC5 in gemcitabine sensitivity

  2006cites this paper
• Deoxynucleoside Kinases and Their Potential Role in Deoxynucleoside Cytotoxicity

  2006cites this paper
• Cellular Resistance Against Troxacitabine in Human Cell Lines and Pediatric Patient Acute Myeloid Leukemia Blast Cells

  2006cites this paper
• Cell Cycle Dependent Regulation of Deoxycytidine Kinase, Deoxyguanosine Kinase, and Cytosolic 5′-Nucleotidase I Activity in MOLT-4 Cells

  2006cites this paper
• Identification of in Vivo Phosphorylation Sites on Human Deoxycytidine Kinase

  2006cites this paper
• The pattern of deoxycytidine- and deoxyguanosine kinase activity in relation to messenger RNA expression in blood cells from untreated patients with B-cell chronic lymphocytic leukemia.

  2006cites this paper
• Is 3′-deoxy-3′-18F-fluorothymidine a better marker for tumour response than 18F-fluorodeoxyglucose?

  2006cites this paper
• Phase II study of clofarabine in pediatric patients with refractory or relapsed acute lymphoblastic leukemia.

  2006cites this paper
• Gemcitabine resistance due to deoxycytidine kinase deficiency can be reverted by fruitfly deoxynucleoside kinase, DmdNK, in human uterine sarcoma cells

  2006cites this paper
• Overview of ribonucleotide reductase inhibitors: an appealing target in anti-tumour therapy.

  2005cites this paper
• Genomic imbalances in human leukemia and lymphoma detected by comparative genomic hybridization (Review).

  2005cites this paper
• Resistance to 9-β-D-Arabinofuranosyl-2-Fluoroadenine due to Reduced Incorporation into DNA from Competition by Excess Deoxyadenosine Triphosphate: Implications for Different Sensitivities to Nucleoside Analogues

  2005influential citation
• Increased expression of the large subunit of ribonucleotide reductase is involved in resistance to gemcitabine in human mammary adenocarcinoma cells

  2005cites this paper
• Lipid nucleoside conjugates for the treatment of cancer.

  2005cites this paper
• Old and new insights into the mechanisms of action of two nucleoside analogs active in lymphoid malignancies: fludarabine and cladribine (review).

  2005cites this paper
• Activation of deoxycytidine kinase by deoxyadenosine: implications in deoxyadenosine-mediated cytotoxicity.

  2005cites this paper
• The ribonucleotide reductase subunit M2B subcellular localization and functional importance for DNA replication in physiological growth of KB cells.

  2005cites this paper
• High Activity and Incomplete Cross Resistance of Nucleoside Analogues Cladribine and Fludarabine Versus Ara-C on Leukemic Cells From Patients With AML

  2005cites this paper
• Clofarabine in the treatment of acute myeloid leukaemia and acute lymphoblastic leukaemia: a review

  2005cites this paper
• Characterization of a Gemcitabine-Resistant Murine Leukemic Cell Line

  2004cites this paper
• Determinants of sensitivity and resistance to gemcitabine: The roles of human equilibrative nucleoside transporter 1 and deoxycytidine kinase in non‐small cell lung cancer

  2004cites this paper
• Pharmacogenetics of neoplastic diseases: new trends.

  2004cites this paper
• Metabolism of 3'-deoxy-3'-[F-18]fluorothymidine in proliferating A549 cells: validations for positron emission tomography.

  2004cites this paper
• Nucleoside transporters in chronic lymphocytic leukaemia

  2004cites this paper
• Structure of human dCK suggests strategies to improve anticancer and antiviral therapy

  2003cites this paper
• Phase I and Pharmacokinetic Study of Triapine , a Potent Ribonucleotide Reductase Inhibitor , Administered Daily for Five Days in Patients with Advanced Solid Tumors 1

  2003cites this paper
• Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors.

  2003cites this paper
• Pharmacogenetics and Proteomics of Anticancer Drugs in Non-Hodgkin's Lymphoma

  2003cites this paper
• Substrate specificity and phosphorylation of antiviral and anticancer nucleoside analogues by human deoxyribonucleoside kinases and ribonucleoside kinases

  2003influential citation
• Achieving the Ultimate Physiological Goal in Transition State Analogue Inhibitors for Purine Nucleoside Phosphorylase*

  2003cites this paper
• Pharmacological Basis for Cladribine Resistance

  2003influential citation